Study Dosage regimen (mg) Disease duration Age (y) (SD) Sex(M: F) BMI (kg/m2 ) (SD) Concomitant treatment Discontinuation Reason Blauvelt et al. [9 ] 30 25.0 (14.8) 36.9 (14.09) 194:150 25.99 (5.72) Monotherapy 32 Adverse event, 10 Withdrew consent, 8 Lost to follow-up, 4 Lack of efficacy, 6 Other, 2 COVID-19 logistics, 1 Guttman-Yassky et al. [18 ] (Group 1) 7.5 30.4 (18.1) 41.5 (15.4) 28: 14 27.9 (6.3) Monotherapy 11 Adverse event, 2 Lack of efficacy, 6 Withdrew consent, 1 Lost to follow-up, 1 Progressive disease, 1 Guttman-Yassky et al. [18 ] (Group 2) 15 22.6 (15.8) 38.5 (15.2) 30: 12 27.4 (6.7) Monotherapy 5 Adverse event, 2 Lack of efficacy, 2 Withdrew consent, 1 Guttman-Yassky et al. [18 ] (Group 3) 30 24.2 (13.6) 39.9 (15.3) 22: 20 27.4 (6.0) Monotherapy 4 Adverse event, 2 Lack of efficacy, 1 Other, 1 Guttman-Yassky et al. [19 ] (Measure up 1 Group 1) 15 20.5 (15.9) 34.1 (12–74) 157: 124 25.8 (6.1) Monotherapy 8 Lost to follow-up, 3 Withdrew consent, 2 Poor efficacy, 2 Adverse event, 1 Guttman-Yassky et al. [19 ] (Measure up 1 Group 2) 30 20.4 (14.3) 33.6 (12–75) 155: 130 25.6 (5.9) Monotherapy 15 Adverse event, 7 Withdrew consent, 4 Lost to follow-up, 2 Other, 1 Systemic rescue medication required, 1 Guttman-Yassky et al. [19 ] (Measure up 2 Group 1) 15 18.8 (13.3) 33.3 (12–74) 155: 121 25.8 (5.6) Monotherapy 16 Adverse event, 7 Other, 4 Poor efficacy, 3 Withdrew consent, 1 Systemic rescue medication required, 1 Guttman-Yassky et al. [19 ] (Measure up 2 Group 2) 30 20.8 (14.3) 34.1 (12–75) 162: 120 25.9 (5.8) Monotherapy 14 Withdrew consent, 5 Adverse event, 4 Other, 3 Lost to follow-up, 1 Systemic rescue medication required, 1 Katoh et al. [20 ] (Group 1) 15 23.0 (14.3) 35.9 (13.2) 68: 23 Weight: 65.1 (14.2) In combination with medium-potency topical corticosteroids once daily 4 Adverse event, 2 Lost to follow-up, 1 Lack of efficacy, 1 Katoh et al. [20 ] (Group 2) 30 20.7 (14.1) 34.7 (12.7) 69: 22 Weight: 66.2 (14.4) In combination with medium-potency topical corticosteroids once daily 6 Withdrew consent, 4 Adverse event, 1 Other, 1 Reich et al. [22 ] (Group 1) 15 22.9 (13.9) 32.5 (13–74) 179: 121 25.8 (6.2) In combination with topical corticosteroids once daily 11 Withdrew consent, 3 Adverse event, 3 Poor efficacy, 2 Lost to follow-up, 2 Other, 1 Reich et al. [22 ] (Group 2) 30 23.1 (16.1) 35.5 (12–72) 190: 107 25.7 (5.4) In combination with topical corticosteroids once daily 10 Other, 4 Adverse event, 3 Withdrew consent, 2 Lost to follow-up, 1 Chiricozzi et al. [24 ] 30 NA 45.91 (15.8) 28: 15 24.6 (3.5) In combination with emollients daily, or with topical corticosteroids of different potencies or topical calcineurin inhibitors 4 Lost to follow-up, 2 Adverse event, 2 Bello et al. [27 ] 15 NA 35.4 (14.1) 8: 2 Weight: 77.2 (8.9) NA 0 NA Hagino et al. [23 ] 15 30.1 (14.3) 41.2 (16.5) 24: 7 24.5 (3.9) In combination with twice daily topical corticosteroids of medium to strongest classes 1 Adverse event, 1 Pereyra-Rodriguez et al. [25 ] 15 or 30 21.1 (11.3) 34.4 (13.5) 23: 20 24.5 (4.9) 9.5% used topical corticosteroids, 6.9% used oral corticosteroids, 2.3% received phototherapy 1 Adverse event, 1 Napolitano et al. [28 ] 30 20.22 (5.21) 28.7 (10.3) 6: 3 NA NA NA NA Feraru et al. [26 ] 15 or 30 NA 51.3 (27–85) 9: 3 NA Topical treatment for AD was offered and prescribed as needed 3 Lack of efficacy, 1 Sustained significant improvement, 2
